ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 151 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $342,000 | +26.2% | 10,200 | 0.0% | 0.23% | +145.7% |
Q3 2016 | $271,000 | +20.4% | 10,200 | 0.0% | 0.09% | +2.2% |
Q2 2016 | $225,000 | -25.0% | 10,200 | 0.0% | 0.09% | -28.0% |
Q1 2016 | $300,000 | -11.0% | 10,200 | 0.0% | 0.12% | +31.6% |
Q4 2015 | $337,000 | -8.7% | 10,200 | 0.0% | 0.10% | +33.8% |
Q3 2015 | $369,000 | -94.4% | 10,200 | -93.0% | 0.07% | -88.5% |
Q2 2015 | $6,582,000 | +41.6% | 146,300 | -3.6% | 0.62% | +41.2% |
Q1 2015 | $4,648,000 | -42.3% | 151,800 | -4.2% | 0.44% | -43.1% |
Q4 2014 | $8,055,000 | +27.9% | 158,400 | -0.4% | 0.77% | +18.8% |
Q3 2014 | $6,296,000 | -33.3% | 159,100 | -27.4% | 0.65% | -19.9% |
Q2 2014 | $9,441,000 | +9.0% | 219,200 | +1.2% | 0.81% | +14.7% |
Q1 2014 | $8,662,000 | +17.4% | 216,600 | -19.9% | 0.71% | +16.9% |
Q4 2013 | $7,377,000 | +26.3% | 270,400 | +6.1% | 0.60% | +11.0% |
Q3 2013 | $5,842,000 | +25.5% | 254,900 | -3.0% | 0.54% | +14.7% |
Q2 2013 | $4,654,000 | – | 262,800 | – | 0.48% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 936,777 | $53,218,000 | 16.69% |
Fairmount Funds Management LLC | 316,952 | $18,006,000 | 6.55% |
ARMISTICE CAPITAL, LLC | 1,836,000 | $104,303,000 | 1.77% |
Soleus Capital Management, L.P. | 182,400 | $10,362,000 | 1.62% |
Portland Global Advisors LLC | 62,635 | $3,558,000 | 0.66% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 40,000 | $2,263,000 | 0.55% |
FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $113,336,000 | 0.53% |
Yorktown Management & Research Co Inc | 10,400 | $591,000 | 0.44% |
Hennion & Walsh Asset Management, Inc. | 120,240 | $6,831,000 | 0.36% |
Virtus ETF Advisers LLC | 9,599 | $545,000 | 0.24% |